A double-blind, randomized study to evaluate the efficacy and safety of TAK-475 [lapaquistat] 100 mg versus placebo in subjects with primary hypercholesterolemia
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Lapaquistat (Primary)
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- 20 Nov 2006 Status change
- 29 Sep 2006 Status change
- 30 Oct 2005 New trial record.